- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acumen Pharmaceuticals Inc (ABOS)
The Acumen Pharmaceuticals share price today is 2.660, view NASDAQ ABOS stock exchange data. Track the latest Acumen Pharmaceuticals share price with real-time updates on ABOS stock performance including market cap, day range, 52-week range and dividend yield. Access ABOS charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.620
2.740
52 wk Range
1.210
3.600
ABOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.6202.740
52 wk Range
1.2103.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABOS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.400
Upside
+178.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 144 ACUMEN PHARMACEUTICALS For: 16 June- Investing.com
- Form 8K Acumen Pharmaceuticals Inc For: 12 August
- Investing.com
- Form 8K Acumen Pharmaceuticals Inc For: 12 August
- Investing.com
Form 4 Acumen Pharmaceuticals Inc For: 17 June- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.400
(+178.20% Upside)
Acumen Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Acumen posted Q2 2026 adjusted EPS of -$0.45, missing estimates of -$0.36 by 25%; shares fell 2.02% premarket to $2.42.
- Cash and marketable securities totaled $110.2M at quarter-end, sufficient to fund operations into early 2027.
- Phase II ALTITUDE-AD trial of sabirnetug remains on track for top-line data in late 2026; virtual investor day set for Sept. 16.
- Company nominated two blood-brain barrier delivery candidates (ACU301, ACU401); IND filing planned for mid-2027.
- R&D expenses declined to $27.8M from prior year; management cited oligomer-targeting approach as potential safety advantage over competitors.
Last Updated: 12-08-2026, 06:12 pm
Read Full TranscriptEarnings
Latest Release
12-08-2026
EPS / Forecast
-0.45 / -0.36
Revenue / Forecast
-- / --
Compare ABOS to Peers and Sector
Metrics to compare | ABOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −2.8x | −0.4x | |
PEG Ratio | −0.07 | −0.04 | 0.00 | |
Price/Book | 3.4x | 2.1x | 2.6x | |
Price / LTM Sales | - | 139.1x | 3.1x | |
Upside (Analyst Target) | 195.2% | 256.1% | 47.9% | |
Fair Value Upside | Unlock | 9.8% | 6.3% | Unlock |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Acumen Pharmaceuticals (ABOS) Share Price Today?
The Acumen Pharmaceuticals share price today is 2.660.
What is the current Acumen Pharmaceuticals (ABOS) share price and day range?
As of 17-08-2026, the Acumen Pharmaceuticals share price is 2.660, with a previous close of 2.670. The share price has ranged from 2.620 to 2.740 today, while the 52-week range spans from 1.210 to 3.600.
What Is the Acumen Pharmaceuticals Market Cap?
As of today, Acumen Pharmaceuticals market cap is 193.090M.
What Is the Acumen Pharmaceuticals (ABOS) Share Price Target?
The average 12-month share price target for Acumen Pharmaceuticals is 7.400, with a high estimate of 10 and a low estimate of 4. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +178.20% Upside potential.
What Is Acumen Pharmaceuticals's Earnings Per Share (TTM)?
The Acumen Pharmaceuticals EPS (TTM) is -1.637.
When Is the Next Acumen Pharmaceuticals Earnings Date?
Acumen Pharmaceuticals will release its next earnings report on 16-11-2026.
From a Technical Analysis Perspective, Is ABOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Acumen Pharmaceuticals Trade On?
Acumen Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Acumen Pharmaceuticals?
The stock symbol for Acumen Pharmaceuticals is "ABOS."
How Many Times Has Acumen Pharmaceuticals Stock Split?
Acumen Pharmaceuticals has split 0 times.
How Many Employees Does Acumen Pharmaceuticals Have?
Acumen Pharmaceuticals has 61 employees.
What Is the ABOS Premarket Price?
ABOS's last pre-market stock price is 2.658. The pre-market share volume is 1,920.000, and the stock has changed by -0.012, or -0.450%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.